株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

シトクロムP450 11B2ミトコンドリア:パイプライン分析

Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 359842
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.65円で換算しております。
シトクロムP450 11B2ミトコンドリア:パイプライン分析 Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 42 Pages
概要

当レポートでは、シトクロムP450 11B2ミトコンドリアを標的とする薬剤の適応症、開発段階、作用機序、投与経路および分子タイプ別の分析、薬剤の薬理作用に関する記述、これまでの研究開発動向、最新のニュースや発表、薬剤の開発に従事している主な企業の概要、休止/中止されたプロジェクトの情報などをお届けします。

イントロダクション

  • 調査範囲

シトクロムP450 11B2ミトコンドリアの概要

治療薬の開発

シトクロムP450 11B2ミトコンドリア:開発中の製品 - 開発段階別

シトクロムP450 11B2ミトコンドリア:開発中の製品 - 治療範囲別

シトクロムP450 11B2ミトコンドリア:開発中の製品 - 適応症別

シトクロムP450 11B2ミトコンドリア:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

シトクロムP450 11B2ミトコンドリア:企業で開発中の製品

シトクロムP450 11B2ミトコンドリア:大学/機関で開発中の製品

シトクロムP450 11B2ミトコンドリア:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

シトクロムP450 11B2ミトコンドリアの治療薬開発に従事している企業

  • Angion Biomedica Corp.
  • Merck & Co., Inc.
  • Novartis AG

薬剤プロファイル

シトクロムP450 11B2ミトコンドリア:休止中のプロジェクト

シトクロムP450 11B2ミトコンドリア:開発が中止された製品

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Angion Biomedica Corp, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by CinCor Pharma Inc, H2 2019
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Pipeline by Damian Pharma AG, H2 2019
  • Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Recordati SpA, H2 2019
  • Pipeline by Selenity Therapeutics Inc, H2 2019
  • Pipeline by Target Medicals LLC, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
目次
Product Code: GMDHC2072TDB

Summary

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Aldosterone synthase is a steroid hydroxylase cytochrome P450 enzyme involved in the biosynthesis of the mineralocorticoid aldosterone. It is only expressed in the zona glomerulosa of the adrenal cortex and is primarily regulated by the renin-angiotensin system. It synthesizes aldosterone in humans and plays an important role in electrolyte balance and blood pressure. Inhibition of aldosterone synthase is used as a medical treatment for hypertension, heart failure, and renal disorders.

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hormonal Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders and Oncology which include indications Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Hyperaldosteronism, Resistant Hypertension, Cardiometabolic Disease, Cardiovascular Disease, Cushing's Syndrome, Endocrine Gland Disorders, Hypertension, Kidney Fibrosis, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myocardial Fibrosis, Pituitary ACTH Hypersecretion (Cushing Disease), Polycystic Kidney Disease and Primary Hyperaldosteronism.

The latest report Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019, outlays comprehensive information on the Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
  • The report reviews Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Overview
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Companies Involved in Therapeutics Development
  • Angion Biomedica Corp
  • Boehringer Ingelheim International GmbH
  • CinCor Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Damian Pharma AG
  • Laekna Therapeutics Shanghai Co Ltd
  • Merck & Co Inc
  • Recordati SpA
  • Selenity Therapeutics Inc
  • Target Medicals LLC
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Drug Profiles
  • ANG-3586 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BI-689648 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CIN-107 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DP-13 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LAE-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osilodrostat phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SE-6440 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CYP11B2 for Cardiovascular Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CYP11B2 for Chronic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CYP11B2 for Resistant Hypertension - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Dormant Products
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Discontinued Products
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 15, 2019: CHMP adopts positive opinion for Isturisa
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer